|
|
 |
|
Viewing report
|
|
|
|
The CNS Outlook to 2007
Business Insights, July 2002
With sales of up to $52bn in 2001, and a growth rate of over 10%, the CNS market represents the second largest therapeutic segment of the pharmaceutical market, and one of the fastest growing. Although key areas of the CNS market are maturing, notably the anti-depressants and pain segments, areas of rapid expansion remain. In particular the anti-psychotic and multiple sclerosis markets are helping to ensure growth is maintained and that CNS markets continue to attract the attention of pharmaceutical manufacturers in terms of R&D resources and marketing budgets. Constant changing dynamics in the CNS market means that pharmaceutical executives need to keep up-to-date on current and future market developments. The CNS Outlook to 2007 provides an analysis of the 2001 performance in the major CNS markets,(namely Alzheimer''s disease, depression, epilepsy, migraine, multiple sclerosis, pain, Parkinson''s disease and schizophrenia).Building upon the primary research in this report, key market data is allied to competitive analysis to provide historical and forecast future product sales along with strategic insight into how companies can exploit opportunities in this market.
Customers who bought this item also bought
CNS Therapeutics - Global Strategic Business Report
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Clinical Trial Recruitment in Central Nervous System Disorders - Highest Number of Patients were Recruited for Clinical Trials in Schizophrenia
The Central Nervous Systems Market 2010 Report
The CNS Pipeline Fact Book - What's in Clinical Development
Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
The Neurotechnology Industry 2011 Report
Pain Therapeutics - Drugs, Markets and Companies
The CNS Market Outlook to 2010
Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
|
|
|
|
